Strategic licensing agreement enables ZoeNCure to build a high-potency, ADC pipeline targeting severe gastrointestinal and liver cancers in India.
ZoeNCure Therapeutics Secures License for Novel Antibody Platform from Styx Biotechnologies to Advance Next-Generation ADCs for Liver Cancer
Strategic licensing agreement enables ZoeNCure to build a high-potency, ADC pipeline targeting severe gastrointestinal and liver cancers in India....
By Dhallo News · September 4, 2026 at 6:26 PM IST

Source: The Hindu - General
SOURCE: The Hindu - General
ORIGINAL REPORT: Click here
DHALLO EDITORIAL STATUS: Aggregated & reviewed
Have feedback on this article?Report error or suggestion
